Firefly Neuroscience (NASDAQ: AIFF) has announced a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes.
Through its acquisition of closely held Evoke Neuroscience, and the successful execution of its key internal growth initiatives, Firefly ended 2025 partnered with 99 commercial users who completed a total of more than 10,800 EEG/ERP brain scans.
The year-over-year increases in partner sites and EEG/ERP clinical assessments represent growth of 1,880% and 3,227%, respectively, since the end of 2024.
In a statement, Greg Lipschitz, CEO of Firefly, commented, “As demonstrated by this significant expansion of our commercial footprint and meaningful increase in our brain scan volumes, we continue to successfully execute against the key pillars of our growth strategy. Our mission is to harness the power of AI and EEG/ERP to transform neuroscience and clinical development. With an exponentially growing foundation of clean data, and by deploying NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing, the Company believes that it is poised to make additional new breakthroughs in cognitive brain biomarker discovery, and to fulfill its goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”
